Trulieve Cannabis (TRLV) just opened a new medical cannabis dispensary in Dunwoody, Georgia, linking its physical footprint expansion to a grand opening event that could catch investors’ attention.
Recent trading shows Trulieve Cannabis with a 1-day share price return of 2.74% and a 30-day share price gain of 20.41%, while the 1-year total shareholder return of 72.40% and 3-year total shareholder return of 60.28% point to momentum that has been building, supported by moves such as the Dunwoody opening and its upcoming institutional investor conference appearance on 9 September 2026.
Compare Trulieve Cannabis's expansion story with other hand picked operators by scanning 15 high quality undiscovered gems, which may be building under the radar in their own niches.
Trulieve Cannabis has momentum in Georgia and a stock that has already moved hard. Does the current price still offer a payoff that justifies the risk, once the valuation work starts to bite?
Most Popular Narrative: 36% Undervalued
Trulieve Cannabis closed at $11.62, while the most followed narrative anchors fair value at $18.18. The valuation gap rests heavily on future cash flow and regulatory tailwinds rather than recent share price strength.
A strong cash position of US$353 million against US$290 million in debt and positive free cash flow of US$42 million in the quarter provide room to fund new stores, production upgrades and possible acquisitions, which can influence future revenue and earnings power.
See why 6 investors see Trulieve Cannabis as 36% undervalued.
Result: Fair Value of $18.18 (UNDERVALUED)
Still, the Trulieve Cannabis story leans heavily on federal rescheduling benefits and new state programs, which could disappoint if rules, timelines or patient uptake fall short.
Find out about the key risks to this Trulieve Cannabis narrative.
Next Steps
Mixed signals in the Trulieve Cannabis story so far. Move quickly, test the numbers against your own expectations, and pressure check both the 3 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Trulieve Cannabis?
If Trulieve Cannabis has you thinking harder about where the next edge might be, do not stop with a single ticker. Broaden your watchlist and let the data work for you.
- Target potential upside by scanning 35 high quality undervalued stocks that pair quality fundamentals with prices the market has not fully reflected yet.
- Strengthen capital protection by reviewing 11 resilient stocks with low risk scores, which is designed for resilience when you want fewer surprises in your portfolio.
- Spot early movers by checking the 3 elite penny stocks with strong financials that pass tighter financial filters instead of relying on hype alone.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com